Don’t miss the latest developments in business and finance.

Wyeth falls 6.64% in two days on poor Q2 outcome

Image
Capital Market
Last Updated : Nov 05 2013 | 11:58 PM IST

Wyeth fell 2.94% at Rs 610.65 at 11:41 IST on BSE, with the stock falling for second day in a row after reporting poor Q2 result.

Meanwhile, the S&P BSE Sensex was down 228.75 points, or 1.07%, to 21,011.81

On BSE, 769 shares were traded in the counter as against an average daily volume of 2,881 shares in the past one quarter.

The stock hit a high of Rs 627 and a low of Rs 608.15 so far during the day. The stock had hit a 52-week high of Rs 989 on 30 November 2012. The stock had hit a 52-week low of Rs 553.05 on 6 September 2013.

The stock outperformed the market over the past one month till 3 November 2013, surging 8.25% compared with the Sensex's 6.72% rise. The scrip, however, underperformed the market in past one quarter, falling 4.54% as against Sensex's 10.83% rise.

The small-cap company has an equity capital of Rs 22.72 crore. Face value per share is Rs 10.

More From This Section

Shares of Wyeth lost 6.64% in two trading days from a recent high of Rs 654.05 on 1 November 2013 after the company reported poor Q2 result after market hours on Friday, 1 November 2013. The stock lost 3.81% to Rs 629.15 on Sunday, 3 November 2013. The stock exchanges had conducted a special live trading session on Sunday, 3 November, 2013, on account of Muhurat trading on Diwali. The stock market remained closed on Monday, 4 November 2013, on account of Diwali-Balipratipada.

Wyeth's net profit fell 39.2% to Rs 18.38 crore on 9.9% rise in net sales to Rs 168.76 crore in Q2 September 2013 over Q2 September 2012.

Wyeth is one of the Indian listed subsidiary companies of Pfizer Inc, the world's largest research-driven pharmaceutical and health care products companies. Its products are leaders in many of the therapeutic segments in which the Company has a presence, viz. Oral Contraceptive, Hormone Therapy and Folic Acid markets. Wyeth Limited has brought to India innovative and leading medicines which have improved the quality of life of patients in the country.

Powered by Capital Market - Live News

Also Read

First Published: Nov 05 2013 | 11:39 AM IST

Next Story